No. For PCR, MMP members are removed from Medicaid reporting and are included in only Medicare reporting.
HEDIS 2019
FAQ Directory: HEDIS
Filter Results
- Save
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
Save your favorite pages and receive notifications whenever they’re updated.
You will be prompted to log in to your NCQA account.
- Email
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
Share this page with a friend or colleague by Email.
We do not share your information with third parties.
- Print
Print this page.
Print this page.
10.15.2018 Plan All-Cause Readmissions In General Guideline 15: Members With Dual Enrollment, the Medicare-Medicaid (MMP) subhead indicates that these members must be in both the Medicaid and Medicare HEDIS reports. Does this apply to Plan All-Cause Readmissions (PCR)?
10.15.2018 Follow-Up After ED visit for People With Multiple High-Risk Chronic Conditions In Step 2 (Exclusions), ED visits followed by admission to an inpatient care setting on the date of the visit or within 7 days after the visit are excluded. Should ED visits that result in an inpatient stay (when the ED date of service occurs any time during the admission [admission date through discharge date]) also be excluded?
10.15.2018 Required Exclusions Are members who are excluded because of hospice, advanced illness, frailty, Institutional SNP (I-SNP) or living long-term in an institution (LTI) included in the “Number of required exclusions” data element?
10.15.2018 Plan All-Cause Readmissions Organizations are instructed to use the file run date to determine the member’s SES stratification in the last 3 months of the continuous enrollment period. For the PCR measure, the continuous enrollment period is 365 days prior to the Index Discharge Date through 30 days after that date. How is a member’s SES stratification determined if the run date falls after the end of the continuous enrollment period?
When determining the SES stratification for PCR, use the last month of the continuous enrollment period, regardless of the run date. For example, if the continuous enrollment period ends July 1, use May, June and July to assess the member’s SES stratification, regardless of the run date of the July Monthly Membership Detail Data File.
HEDIS 2019
10.15.2018 Rules for Allowable Adjustments The General Guidelines in the Rules for Allowable Adjustments states, “use the separate HEDIS Adjustments VSD to calculate measure rates stemming from adjusted measure specification.” Does this mean that ONLY the HEDIS Adjustments VSD must be used?
No. The Allowable Adjustments VSD does not contain the standard HEDIS value sets; standard HEDIS value sets are in the HEDIS 2019 Volume 2 VSD. The Allowable Adjustments VSD includes only SNOMED and LOINC codes that are not in the Volume 2 VSD. Organizations collecting data using the rules for allowable adjustments can elect (but are not required) to use the value sets in the Allowable Adjustments VSD.
HEDIS 2019
9.14.2018 Risk of Continued Opioid Use In the HEDIS 2019 Volume 2 Technical Specifications, the Risk of Continued Opioid Use (COU) measure includes the Medicare product line; however, this measure was not included in the CMS Reporting Requirements memo for HEDIS 2019. Given this discrepancy, is the COU measure reported by Medicare plans?
7.16.2018 Use of Opioids at High Dosage Why is buprenorphine included in the Use of Opioids From Multiple Providers (UOP) and Risk of Continued Opioid Use (COU) measures, but not in the Use of Opioids at High Dosage (UOD) measure?
Unlike UOP and COU, UOD requires the conversion of all dispensed opioids into morphine milligram equivalents (MME). The most current MME conversion file, published by the Centers for Disease Control and Prevention, removes buprenorphine, a partial opioid agonist, and states that the drug is not likely to be associated with overdose in the same dose-dependent manner as pure opioid agonists. NCQA removed it from the UOD measure in HEDIS 2019. This change aligns with the decision made by the Pharmacy Quality Alliance, the organization that developed the measure from which UOD was adapted for use in HEDIS.
HEDIS 2019
7.16.2018 General Guidelines Does a member enrolled in palliative care meet criteria for the hospice exclusion outlined in General Guideline 17?
Palliative care is not the same as hospice care because it can begin when a patient is diagnosed or is undergoing treatment and may not indicate being near end of life. The hospice exclusion requires evidence that the member is receiving hospices services. Documentation that a member is in palliative care is not part of the exclusion.
HEDIS 2019
5.15.2018 ECDS How do ECDS measures differ from the eMeasures in Meaningful Use (eCQMs)?
HEDIS ECDS measures are similar to eCQMs in structure, but although eCQMs are reported at the provider level, using data from an EHR, ECDS measures are reported at the health-plan level, using data from multiple sources to form a complete picture of the patient’s experience across the care continuum.
HEDIS 2018
5.15.2018 ECDS What data standards does NCQA use to specify ECDS measures?
5.15.2018 ECDS Do you utilize FHIR to specify ECDS measures?
5.02.2018 Plan All-Cause Readmissions For the Count of Expected 30-Day Readmissions, we are using the calculation in Step 6 in HEDIS Volume 2 (pg. 384), but IDSS is calculating differently. Is this calculation correct?
The calculation for the Count of Expected 30-Day Readmissions is incorrect in Volume 2. IDSS currently calculates this field by using the formula "Count of Expected 30-Day Readmissions" = "Expected Readmission Rate" * "Count of Index Stays".
Please provide data for the Expected Readmission Rate and the Count of Index Stays and IDSS will use these values to generate the correct calculation.
HEDIS 2018